Dose Escalation Study of MLN0128 in Relapsed or Refractory Multiple Myeloma or Waldenstrom Macroglobulinemia
Status:
Completed
Trial end date:
2013-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the safety, tolerability, maximum tolerated dose
and pharmacokinetics of MLN0128 in patients with Relapsed or Refractory Multiple Myeloma or
Waldenstrom Macroglobulinemia